POSB74 Belantamab Mafodotin as the First-in-Class Anti-BCMA Treatment for Relapsed/Refractory Multiple Myeloma: A Budget Impact and Cost-Effectiveness Analysis
Speranza, G, Diliberto, MJ, Fattore, C, Fiorentino, F, Prawitz, T, Nikolaou, A, Samele, R
Published in Value in health (01.01.2022)
Published in Value in health (01.01.2022)
Get full text
Journal Article